Merck & Co., Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Merck & Co., Inc. (MRK) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2018-02-27
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2017 was $0.00.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2015 was $321.00M.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-27 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-27 |
| 2015-12-31 | $321.00M 10-K · filed 2018-02-27 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 |
| 2013-12-31 | $27.00M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |